Biotest AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
Expansion of plasma protein product range
- Approval for Albiomin 5% and Albiomin 20% in European core markets
- Preparation for use in acute medicine
- Possibility of more efficient use of plasma as a raw material
Dreieich, 12 January 2009. Biotest has been granted approval by the
responsible authorities for the albumin preparations Albiomin 5% and
Albiomin 20% under the European Mutual Recognition Procedure (MRP). The
approvals for human albumin already in place in Europe have therefore been
extended to six further important European markets.
Albiomin is a plasma expander, which can be used to stabilise circulating
blood volume after heavy blood loss. The preparation is available as 5 %
and 20 % solutions. Albiomin 5% is used for volume substitution with a
long-term effect, particularly in the field of acute medicine. Albiomin 20%
is additionally used in internal medicine and surgery, for example in the
treatment of shock, burns, cirrhosis of the liver or toxic processes.
Produced from human blood plasma, Biotest's albumin preparation has many
advantages over synthetic plasma expanders. Side effects are rare, the risk
of an overdose and circulation overload is lower, and naturally-based
products are also better able to stabilise blood pressure.
Biotest has further extended its own product range with Albiomin 5% and
Albiomin 20%. The approval creates the precondition for additional
expansion of the company's presence in European core markets and more
efficient use of human blood plasma as a raw material.
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,950
employees worldwide and its shares are listed in the Frankfurt Stock
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth,
Tel: +49 (0) 6103 801-520,
Fax: +49 (0) 6103 801-347
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
12.01.2009 Financial News transmitted by DGAP
Issuer: Biotest AG
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service